London · Delayed Price · Currency is GBP · Price in GBX IP Group Earnings Call Transcripts
Fiscal Year 2025
-
NAV per share grew 13% year-over-year, driven by a major royalty interest in Pfizer's obesity drug, strong cash exits, and disciplined buybacks. Portfolio companies raised GBP 900 million in third-party capital, and the group remains focused on deep tech, clean tech, and life sciences.
-
Strong H1 progress with GBP 30m in exits, robust cash position, and NAV per share rising to GBP 1. Hinge Health IPO and Oxford Nanopore outperformance drove value, while buybacks accelerated. Confident in GBP 250m exit target by 2027 and securing new scale-up mandates.
-
The event outlined a strategy focused on leveraging the U.K.'s scientific strengths to build and scale deep tech businesses, addressing global mega trends in energy, healthcare, and digitalization. With strong government support and a robust investment pipeline, the group is well positioned for growth and value creation.
-
The meeting highlighted record cash realizations, a strong cash position, and decisive cost reductions. Strategic focus remains on addressing the NAV discount, expanding buybacks, and building scale-up capital, with all AGM resolutions passed and robust shareholder engagement throughout.
Fiscal Year 2024
-
Cash exits reached GBP 183 million in 2024, outpacing a sluggish VC market, while accelerated buybacks retired over 10% of shares. Despite a 15% NAV per share decline due to write-downs in key holdings, cost reductions and a strong pipeline position the group for future growth.
-
Portfolio exits accelerated in H1 2024, enabling significant capital returns despite a 9% NAV per share decline driven by Nanopore. Cost reductions and a strong cash position support further buybacks, while momentum is building for additional exits and value creation in H2.